Monday, July 1, 2013
Buysiders think biotech is
poised - and now financed - for future growth even if markets take a brief
pause at some point this quarter. Generalist investors are at long last helping
to fuel demand for new biotech issuances, including an expansion of the
first legitimate IPO window in a decade.
On June 18, IPOs in aggregate
crossed the $1 billion threshold with 19 deals sold over 4.7 months. The year
to date total now stands at 25, with at least 13 companies
still in the queue (see "IPO Queue," A2).